Contact
Please use this form to send email to PR contact of this press release:
Planned Shipment of IV Ketamine to 100+ US Pharmacies; Potential of $330 Million in Payments & Royalties: NASDAQ; NRXP
TO:
Matthew Duffy, Chief Business Officer
NRx Pharmaceuticals, Inc.
+1 484-254-6134